2 Min Read
ZURICH, May 18 (Reuters) - The Swiss blue-chip SMI was seen opening down 0.3 percent at 8,978 points on Thursday, according to premarket indications by bank Julius Baer .
Here are some of the main factors expected to affect Swiss stocks:
Switzerland's second-biggest bank holds an extraordinary general meeting for shareholders to vote on a proposed capital increase, through which it hopes to raise around 4 billion Swiss francs to strengthen its balance sheet and fund a restructuring under CEO Tidjane Thiam.
For more, click on
* Aevis Victoria SA said its Swiss Medical Network SA had submitted an acquisition offer to all shareholders of Holding du Tilleul Biel/Bienne SA and invites Clinique des Tilleuls to join its network.
* Kuehne + Nagel said it was expanding its partnership with GlaxoSmithKline with a new UK domestic distribution contract.
* Roche said it had first Phase I efficacy and safety data on CEA-TCB (CEA CD3TCB), a novel T-cell bispecific antibody targeting solid tumours.
* SHL Telemedicine Ltd. said it received a statement from major shareholder Cai Mengke, contradicting a resolution of the company's last AGM that reclassified her as a controlling shareholder acting in concert with another shareholder.
* Zueblin Immobilien Holding AG said it completed the financial year 2016/17 with a profit of 29.9 million Swiss francs, compared with an overall net loss of 18.9 million francs in the previous year, and said it may consider paying a dividend to shareholders.
* The Swiss National Bank is still ready to intervene in the forex market if necessary, Chairman Thomas Jordan was quoted as saying in a newspaper interview.
Reporting by Zurich newsroom